White Guide and Orange Guide Formatting Project - Pfizer

Orange Guide – Chapter 3: Support of External Organizations
A coalition is an activity or project where Pfizer and two or more other organizations (either for-profit
or not-for-profit) formally and publicly join forces over a period of time to advance a common policy or
disease awareness objective. Pfizer is involved in advancing the goals of the coalition in addition to
Pfizer being a member of the coalition. With respect to healthcare-related coalitions, the majority of
coalition members must be non-commercial, non-manufacturer organizations and they should have
ultimate control over the coalition and its message. Pfizer may provide funds, resources or expertise to
the coalition. The coalition controls the goals, activities and messaging, subject to Pfizer’s limited right
to review for accuracy and compliance with relevant laws and regulations, industry codes, external
standards and internal Pfizer policies and procedures.
Examples: U.S. Public Affairs participates in a coalition with national and state-based
cancer advocacy groups to work together on reimbursement and coverage challenges;
funding of a coalition to organize a series of events and develop white papers on relevant
public policy topics.
Colleagues That May Provide Funding: Coalitions can be funded by colleagues in the U.S.
Biopharmaceutical Business (except Sales Colleagues), Pfizer Medical and PEAC groups.
Approval Process: All requests to participate in a coalition must be submitted by
appropriate colleagues using the Funding Request Form at http://InterAct.Pfizer.com. All
such requests are subject to review and approval by Legal. Colleagues should discuss all
pertinent facts about a coalition with Legal prior to submitting the Funding Request Form
for approval.
Collaborations and Coalitions – Tangible Benefit and Disclosure of Pfizer Involvement
Given the nature of Pfizer’s involvement in collaborations and coalitions, including the provision of
strategic input and often the rights to use the output of the activities, these categories provide Pfizer
with a tangible benefit and should not be considered a charitable contribution even if the receiving
organization is a not-for-profit entity.
Pfizer’s participation in collaborations and coalitions must also be appropriately disclosed in all resulting
materials in a manner that does not imply that funding was provided via an independent grant (e.g.
“Developed in collaboration with Pfizer” versus “Funding Support Provided by Pfizer”).
66
Rev. 09/12
Page 22 of 26